pembrolizumab
merck
['sclc', 'pembro', 'nsclc', 'lcsm,(-blcsm)']
pembrolizumab produces prolonged survival in nsclc with pd-l1 tps 90% #asco22 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.